Gen-Probe Licenses from Corixa Rights to Develop Molecular Diagnostic Tests for Potential Markers of Genitourinary and Other Can
2005年1月5日 - 9:30PM
PRニュース・ワイアー (英語)
Gen-Probe Licenses from Corixa Rights to Develop Molecular
Diagnostic Tests for Potential Markers of Genitourinary and Other
Cancers - Agreement Broadens and Accelerates Gen-Probe's Strategic
Move into Oncology Diagnostics, Moves Additional Corixa Discoveries
Toward Product Commercialization - SAN DIEGO and SEATTLE, Jan. 5
/PRNewswire-FirstCall/ -- Gen-Probe (NASDAQ:GPRO) has licensed from
Corixa (NASDAQ:CRXA) the rights to develop molecular diagnostic
tests for approximately 50 potential genetic markers in the areas
of prostate, ovarian, cervical, kidney, lung and colon cancer, the
companies announced today. "This agreement with Corixa is a
significant step forward in our long-term strategy to become a
leader in cancer diagnostics," said Henry L. Nordhoff, chairman,
president and chief executive officer of Gen-Probe. "We believe the
next two to three years will be a time of strong product sales
growth for Gen-Probe, driven by the roll-out of the TIGRIS(R)
system, continued international expansion in blood screening, and
the U.S. approvals of our Procleix(R) Ultrio(TM) and West Nile
virus assays. We expect this agreement with Corixa, together with
our collaborations with DiagnoCure, AdnaGen and others, to drive
another major cycle of longer-term growth." Under the terms of the
agreement, Gen-Probe will gain access to certain Corixa
intellectual property covering multiple genetic sequences related
to potential markers for various cancers. These markers include
AMACR for prostate and colon cancers, CA125 for ovarian cancer, and
L523S for cervical and lung cancers. In exchange, Gen-Probe will
pay Corixa a $1.6 million initial access fee, and an additional
$3.2 million in two equal access fees in January of 2006 and 2007,
unless Gen-Probe terminates the agreement. Gen-Probe also will pay
Corixa up to $2 million on a product-by-product basis if certain
regulatory and commercial milestones are achieved. In addition,
Gen-Probe will pay Corixa royalties on sales of any products
developed using Corixa's intellectual property. "We are pleased to
have entered into a broad relationship with Gen-Probe for the
development of multiple nucleic-acid based diagnostics," said
Steven Gillis, Ph.D. chairman and chief executive officer of
Corixa. "The transaction underscores value associated with a number
of prior Corixa discoveries and our ability to move these
discoveries forward toward possible commercialization. We welcome
Gen-Probe as the most recent of Corixa's diagnostic partners.
Previous licensees include DakoCytomation, Abbott Laboratories and
Ortho Biotechnology." About Gen-Probe Gen-Probe Incorporated is a
global leader in the development, manufacture and marketing of
rapid, accurate and cost-effective nucleic acid tests for
diagnosing human diseases and screening donated human blood. Using
its patented technologies, Gen-Probe has received FDA approvals or
clearances for a broad portfolio of products that detect a variety
of infectious microorganisms, including those causing sexually
transmitted diseases, tuberculosis, strep throat, pneumonia and
fungal infections. In addition, Gen-Probe's TIGRIS instrument is
the only fully automated, high-throughput system in the molecular
diagnostics industry. The Company also developed and manufactures
the only FDA-approved blood screening assay for the simultaneous
detection of HIV-1 and HCV, which is marketed by Chiron
Corporation. Gen-Probe has more than 20 years of nucleic acid
detection research and product development experience, and its
products are used daily in clinical laboratories and blood
collection centers throughout the world. Gen-Probe is headquartered
in San Diego, California and employs approximately 900 people. For
more information, go to http://www.gen-probe.com/. About Corixa
Corixa is a biopharmaceutical company developing vaccine adjuvants
and immunology based products that manage human diseases. Corixa's
products are currently in multiple clinical development programs,
including several that have advanced to and through late stage
clinical trials. The company partners with numerous developers and
marketers of pharmaceuticals, targeting products that are Powered
by Corixa(TM) technology with the goal of making its potential
products available to patients around the world. Corixa was founded
in 1994 and is headquartered in Seattle, with additional operations
in Hamilton, Montana. For more information, please visit Corixa's
Web site at http://www.corixa.com/. Gen-Probe Caution Regarding
Forward-Looking Statements Any statements in this press release
about Gen-Probe's expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical
facts and are forward-looking statements. These statements are
often, but not always, made through the use of words or phrases
such as "believe," "will," "expect," "anticipate," "estimate,"
"intend," "plan," and "would." For example, statements concerning
intellectual property, future development, the potential of the
cancer diagnostics market, payment of license fees and royalties,
regulatory and commercial milestones, future growth, and the human
papillomavirus market are forward-looking statements.
Forward-looking statements are not guarantees of performance. They
involve known and unknown risks, uncertainties and assumptions that
may cause actual results, levels of activity, performance or
achievements to differ materially from those expressed or implied
by any forward-looking statement. Some of the risks, uncertainties
and assumptions that could cause actual results to differ
materially from estimates or projections in the forward-looking
statement include, but are not limited to: (i) the risk that
Corixa's intellectual property will be infringed or invalidated,
(ii) the risk that Gen-Probe's development of cancer diagnostics
will not be successful, (iii) the risk that the cancer diagnostics
market may not grow as expected, (iv) the risk that Gen-Probe may
not be able to maintain its current corporate collaborations,
including with Corixa, or enter into new ones, and (v) the risk
that Gen-Probe will not enter the market for human papillomavirus
testing successfully or economically. For additional information
about risks and uncertainties Gen-Probe faces and a discussion of
the Company's financial statements and footnotes, see documents
filed with the SEC, including the Report on Form 10-Q for the
fiscal quarter ended September 30, 2004 and all periodic filings
made with the SEC. Gen-Probe assumes no obligation and expressly
disclaims any duty to update any forward-looking statement to
reflect events or circumstances after the date of this news release
or to reflect the occurrence of subsequent events. Corixa
Forward-Looking Statements This press release contains
forward-looking statements, including statements regarding the
commercial potential for molecular diagnostic tests for potential
markers of genitourinary and other cancers, and other statements
about our plans, objectives, intentions and expectations.
Forward-looking statements are based on the opinions and estimates
of management at the time the statements are made. They are subject
to certain risks and uncertainties that could cause actual results
to differ materially from any future results, performance or
achievements expressed or implied by such statements. Factors that
could affect Corixa's actual results include, but are not limited
to the "Factors Affecting Our Operating Results, Our Business and
Our Stock Price," described in our Quarterly Report on Form 10-Q
for the quarter ended September, 2004, copies of which are
available from our investor relations department. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release.
Gen-Probe Michael Watts Sr. director, investor relations and
corporate communications 858-410-8673 Corixa Jim DeNike Sr.
director, corporate communications 206-366-3720 DATASOURCE:
Gen-Probe Incorporated CONTACT: Michael Watts, Sr. director,
investor relations and corporate communications of Gen-Probe,
+1-858-410-8673; or Jim DeNike, Sr. director, corporate
communications of Corixa, +1-206-366-3720 Web site:
http://www.corixa.com/ http://www.gen-probe.com/
Copyright
Corixa (NASDAQ:CRXA)
過去 株価チャート
から 5 2024 まで 6 2024
Corixa (NASDAQ:CRXA)
過去 株価チャート
から 6 2023 まで 6 2024